Blog
RSS FeedPosted by Michael Wonder on 14 Oct 2021
Drug pricing tug of war expected over CAR-T therapy Kymriah
14 October 2021 - The world’s first CAR-T therapy, Kymriah (tisagenlecleucel), passed the review of a panel at the Health ...
Posted by Michael Wonder on 11 Oct 2021
Takeda's ovarian cancer drug Zejula gets expanded insurance benefit
1 October 2021 - Takeda Korea said its ovarian cancer treatment Zejula would receive expanded health insurance coverage as maintenance ...
Posted by Michael Wonder on 28 Sep 2021
A review of utility measurement methods used in pharmacoeconomic submissions to HIRA in South Korea: methodological consistency and areas for improvement
28 September 2021 - This study, which was conducted as part of a project for revision of the pharmacoeconomic ...
Posted by Michael Wonder on 27 Sep 2021
Will price of Avastin, staple in anti-cancer therapy, go down?
27 September 2021 - Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, is almost a staple in anticancer treatment ...
Posted by Michael Wonder on 19 Sep 2021
Manufacturers’ perceptions of the decision-making process for new drug reimbursement in South Korea
17 September 2021 - This study aimed to evaluate manufacturers’ perceptions of the decision-making process for new drug reimbursement and to ...
Posted by Michael Wonder on 09 Sep 2021
Insurance benefits for Pfizer’s heart drug Vyndamax uncertain
9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s ...
Posted by Michael Wonder on 07 Sep 2021
Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer
7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...
Posted by Michael Wonder on 03 Sep 2021
Acute myeloid leukaemia drug Xospata nears getting insurance benefits
3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step ...
Posted by Michael Wonder on 02 Sep 2021
Pfizer’s acromegaly treatment receives reimbursement
2 September 2021 - Pfizer Korea said Thursday that the Ministry of Health and Welfare would begin to reimburse Somavert, ...
Posted by Michael Wonder on 02 Sep 2021
CAR-T therapy Kymriah fails to get insurance benefits
2 September 2021 - The first CAR-T therapy, Kymriah (ingredient: tisagenlecleucel), failed to pass the review of a panel at ...
Posted by Michael Wonder on 01 Sep 2021
Cancer treatments account for 9.3% of total drug claims in 2020
1 September 2021 - The National Health Insurance Service (NHIS) said that the reimbursement claims for anticancer drugs last year ...
Posted by Michael Wonder on 30 Aug 2021
Roche to withdraw 2 Parkinson’s drugs from Korean market
27 August 2021 - Roche said it would withdraw Parkinson’s syndrome treatment Madopar 125 mg and 250 mg tablets from ...
Posted by Michael Wonder on 26 Aug 2021
Government eases criteria for haemophilia A drug reimbursement
26 August 2021 - The Government said it would ease the immune tolerance induction treatment criteria for haemophilia A drug ...
Posted by Michael Wonder on 25 Aug 2021
Avastin biosimilar may bring insurance benefits for Tecentriq
25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns ...
Posted by Michael Wonder on 18 Aug 2021
Talks to recover reimbursement for dementia treatment aid almost complete
18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...